샘플 요청 목록

 카트 문의
시장보고서
상품코드
1565173

올리고뉴클레오타이드 치료제 시장

Oligonucleotide Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

올리고뉴클레오타이드 치료제 세계 시장은 2030년까지 49억 달러에 달할 것으로 예상됩니다

2023년 28억 달러로 추정되는 올리고뉴클레오티드 치료제 세계 시장은 2030년까지 49억 달러에 달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 8.7%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 안티센스/RNAI 올리고뉴클레오티드 기술은 9.3%의 연평균 복합 성장률(CAGR)을 기록하여 분석 기간이 끝날 때까지 40억 달러에 도달할 것으로 예상됩니다. 기타 기술 분야의 성장률은 분석 기간 동안 CAGR 6.4%로 추정됩니다.

미국 시장은 7억 6,260만 달러로 추정, 중국은 CAGR 7.9%로 성장 전망

미국의 올리고뉴클레오티드 치료제 시장은 2023년 7억 6,260만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023-2030년의 분석 기간 동안 7.9%의 연평균 복합 성장률(CAGR)로 2030년까지 7억 4,490만 달러 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 8.2%와 6.9%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 약 6.9%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

세계 올리고뉴클레오타이드 치료제 시장 - 주요 동향 및 촉진요인 정리

올리고뉴클레오티드 치료제란?

올리고뉴클레오티드 치료제는 합성 올리고뉴클레오티드(DNA 또는 RNA의 짧은 가닥)를 사용하여 세포 내 유전자 발현과 단백질 기능을 조절하는 빠르게 부상하고 있는 약물군입니다. 이들 치료제는 특정 유전자를 침묵시키거나, 복구하거나, 발현을 변화시키도록 설계되었으며, 기존의 저분자 의약품에 비해 표적화 정도가 매우 높습니다. 올리고뉴클레오티드 치료제에는 안티센스 올리고뉴클레오티드(ASO), 저분자 간섭 RNA(siRNA), 앱타머 등이 포함되며, 유전성 질환, 암, 심혈관 질환 등 다양한 질병을 치료하는 데 사용되고 있습니다. 분자 수준에서 질병을 다루는 이러한 능력은 정밀의료의 중요한 발전이며, 지금까지 치료할 수 없었던 질병에 새로운 희망을 주고 있습니다. 유전질환과 희귀질환에 대한 연구가 진행됨에 따라 정밀의학은 제약업계의 중요한 요소로 부상하고 있으며, 과학계와 제약업계 모두 큰 관심을 보이고 있습니다.

기술 혁신은 어떻게 올리고뉴클레오타이드 치료제의 한계를 넓혀가고 있는가?

올리고뉴클레오타이드의 화학, 전달 시스템 및 제조 공정의 기술적 발전은 올리고뉴클레오타이드 치료제의 성공에 매우 중요한 역할을 하고 있습니다. 올리고뉴클레오타이드의 안정성과 생체 이용률을 향상시키는 포스포로티오네이트 백본과 지질 나노입자 전달 시스템 등의 개선으로 혈류 내 불안정성 및 특정 조직 표적화의 어려움과 같은 초기 한계를 극복할 수 있었습니다. 또한 RNA 간섭(RNAi) 및 CRISPR과 같은 유전자 편집 기술의 혁신은 올리고뉴클레오티드 기반 치료의 범위를 크게 확장시켰습니다. 인공지능(AI)과 계산생물학의 발전은 보다 효과적이고 정확한 올리고뉴클레오티드를 설계하여 표적 외 효과를 줄이고 치료 효과를 향상시키는 데 도움을 주고 있습니다. 또한, 고처리량 합성 기술의 발달로 대량의 올리고뉴클레오티드 라이브러리를 신속하게 생산할 수 있게 되어 신약 개발 과정을 가속화할 수 있게 되었습니다. 이러한 기술적 비약적 발전으로 올리고뉴클레오타이드 치료제와 관련된 기존 문제를 극복하고 주류 임상 사용이 점점 더 현실화되고 있습니다.

올리고뉴클레오타이드 치료제는 어떤 질환을 대상으로 하며, 왜 수요가 증가하는가?

올리고뉴클레오타이드의 치료 가능성이 확대됨에 따라 올리고뉴클레오타이드는 광범위한 유전성 질환과 희귀질환을 치료하는 중요한 솔루션으로 자리매김하고 있습니다. 올리고뉴클레오티드 치료제는 결함 유전자를 침묵시키거나 수정하여 질병의 근본 원인을 표적으로 삼을 수 있으며, Spinraza(척수성 근위축증 치료제) 및 Tegsedi(유전성 트랜스실레틴 매개 아밀로이드증 치료제)와 같은 승인된 치료제는 신경근육질환, 종양학 및 대사성 질환에 대한 추가 연구의 발판을 마련했습니다. 종양학에서 올리고뉴클레오티드 치료제는 암 유전자를 억제하거나 암 억제 유전자의 발현을 강화하는 능력을 연구하여 암 치료의 새로운 길을 개척하고 있습니다. 또한, 심혈관계 질환, 안과 질환, 바이러스 감염 등에서도 유망한 치료법으로 주목받고 있습니다. 이러한 치료법은 환자 개개인의 유전적 구성에 따라 맞춤형 치료 옵션을 제공한다는 개별화된 특성이 수요를 주도하고 있으며, 이러한 추세는 정밀의료를 향한 광범위한 움직임과 일치하고 있습니다.

올리고뉴클레오타이드 치료제 시장의 성장을 가속하는 주요 요인은?

올리고뉴클레오티드 치료제 시장의 성장은 주로 승인된 치료제 증가와 치료용도의 확대, RNA 간섭 및 안티센스 올리고뉴클레오티드와 같은 RNA 표적화 기술의 발전으로 미충족 의료 수요가 높은 질병을 치료할 수 있는 새로운 문을 열게 되었습니다. 새로운 문이 열렸습니다. 정밀의료에 대한 관심 증가와 희귀 유전성 질환 치료법 개발은 기존 치료법으로는 불가능한 표적화된 맞춤형 솔루션을 제공한다는 점에서 큰 성장 동력이 되고 있습니다. 또한, 암, 심혈관 질환 및 기타 만성 질환에 대한 지속적인 연구로 인해 올리고뉴클레오티드 기반 치료법에 대한 수요가 증가하고 있습니다. 지질 나노입자, 엑손스킵핑 기술 등 약물 전달 방법의 기술적 발전은 이러한 약물의 효능과 안전성 프로파일을 더욱 향상시키고 있습니다. 생명공학에 대한 투자 증가와 규제 당국의 신속한 의약품 승인에 대한 지원도 시장 확대에 기여하고 있습니다. 제약회사들이 올리고뉴클레오타이드 연구개발에 지속적으로 투자함에 따라 향후 몇 년동안 시장은 강력한 성장세를 보일 것으로 예상됩니다.

조사 대상 기업 예시(주목받는 44개사)

  • Alnylam Pharmaceuticals, Inc.
  • AnaBioTec NV
  • Arrowhead Pharmaceuticals, Inc.
  • Avidity Biosciences
  • Axispharm Laboratories Ltd.
  • Axolabs
  • Bachem AG
  • baseclick GmbH
  • Bio Basic Inc.
  • Biogen, Inc.

    목차

    제1장 조사 방법

    제2장 주요 요약

    • 시장 개요
    • 주요 기업
    • 시장 동향과 촉진요인
    • 세계 시장 전망

    제3장 시장 분석

    • 미국
    • 캐나다
    • 일본
    • 중국
    • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 기타 유럽
    • 아시아태평양
    • 기타 지역

    제4장 경쟁

    LSH 24.10.08

    Global Oligonucleotide Therapeutics Market to Reach US$4.9 Billion by 2030

    The global market for Oligonucleotide Therapeutics estimated at US$2.8 Billion in the year 2023, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2023-2030. Antisense / RNAI Oligonucleotides Technology, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Other Technologies segment is estimated at 6.4% CAGR over the analysis period.

    The U.S. Market is Estimated at US$762.6 Million While China is Forecast to Grow at 7.9% CAGR

    The Oligonucleotide Therapeutics market in the U.S. is estimated at US$762.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$744.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

    Global Oligonucleotide Therapeutics Market – Key Trends & Drivers Summarized

    What Are Oligonucleotide Therapeutics and Why Are They a Game Changer?

    Oligonucleotide therapeutics are a rapidly emerging class of drugs that use synthetic oligonucleotides (short strands of DNA or RNA) to modulate gene expression or protein function within cells. These therapies are designed to silence, repair, or alter the expression of specific genes, making them highly targeted compared to traditional small-molecule drugs. Oligonucleotide therapeutics include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, which are being used to treat a range of diseases, including genetic disorders, cancers, and cardiovascular conditions. Their ability to address diseases at the molecular level represents a significant advancement in precision medicine, offering new hope for previously untreatable conditions. As research into genetic and rare diseases progresses, oligonucleotide therapeutics are becoming a vital component of the pharmaceutical landscape, driving significant interest from both the scientific community and pharmaceutical companies.

    How Are Technological Innovations Pushing the Boundaries of Oligonucleotide Therapeutics?

    Technological advancements in oligonucleotide chemistry, delivery systems, and manufacturing processes are playing a pivotal role in the success of oligonucleotide therapeutics. Early limitations, such as instability in the bloodstream and difficulties in targeting specific tissues, have been addressed through modifications like phosphorothioate backbones and lipid nanoparticle delivery systems, which enhance the stability and bioavailability of oligonucleotides. Furthermore, innovations in RNA interference (RNAi) and gene editing technologies, such as CRISPR, have significantly expanded the scope of oligonucleotide-based therapies. Advances in artificial intelligence (AI) and computational biology are also aiding in the design of more effective and precise oligonucleotides, reducing off-target effects and improving therapeutic efficacy. Additionally, the development of high-throughput synthesis technologies allows for the rapid production of large libraries of oligonucleotides, accelerating drug discovery and development processes. These technological breakthroughs are helping to overcome the traditional challenges associated with oligonucleotide therapeutics, making them increasingly viable for mainstream clinical use.

    What Diseases Are Oligonucleotide Therapeutics Targeting and Why Is Demand Growing?

    The expanding therapeutic potential of oligonucleotides has positioned them as a key solution for addressing a wide range of genetic and rare diseases. One of the primary areas of focus is rare genetic disorders, where oligonucleotide therapeutics can target the root cause of the disease by silencing or modifying defective genes. Approved treatments like Spinraza (for spinal muscular atrophy) and Tegsedi (for hereditary transthyretin-mediated amyloidosis) have set the stage for further exploration into neuromuscular diseases, oncology, and metabolic conditions. In oncology, oligonucleotide therapeutics are being explored for their ability to inhibit oncogenes or enhance the expression of tumor suppressor genes, creating novel avenues for cancer treatment. Additionally, they are showing promise in cardiovascular diseases, ocular disorders, and viral infections. The personalized nature of these therapies is driving demand, as they offer tailored treatment options based on the genetic makeup of individual patients, a trend that aligns with the broader move toward precision medicine.

    What Are the Key Drivers Fueling Growth in the Oligonucleotide Therapeutics Market?

    The growth in the oligonucleotide therapeutics market is driven by several factors, primarily the increasing number of approved therapies and their expanding therapeutic applications. Advances in RNA-targeting technologies, such as RNA interference and antisense oligonucleotides, have opened new doors for treating diseases with high unmet medical needs. The growing focus on precision medicine and the development of treatments for rare genetic disorders are also significant growth drivers, as these therapies offer targeted, personalized solutions that conventional treatments cannot provide. Additionally, ongoing research into cancer, cardiovascular diseases, and other chronic conditions is pushing the demand for oligonucleotide-based therapies. Technological advancements in delivery methods, such as lipid nanoparticles and exon-skipping technologies, are further improving the effectiveness and safety profiles of these drugs. Increased investment in biotechnology, along with regulatory support for accelerated drug approvals, is also contributing to the market’s expansion. As pharmaceutical companies continue to invest in oligonucleotide research and development, the market is expected to see robust growth in the coming years.

    Select Competitors (Total 44 Featured) -

    • Alnylam Pharmaceuticals, Inc.
    • AnaBioTec NV
    • Arrowhead Pharmaceuticals, Inc.
    • Avidity Biosciences
    • Axispharm Laboratories Ltd.
    • Axolabs
    • Bachem AG
    • baseclick GmbH
    • Bio Basic Inc.
    • Biogen, Inc.

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    • 1. MARKET OVERVIEW
      • Influencer Market Insights
      • World Market Trajectories
      • Global Economic Update
      • Oligonucleotide Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
      • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • 2. FOCUS ON SELECT PLAYERS
    • 3. MARKET TRENDS & DRIVERS
      • Rising Incidence of Genetic Disorders and Rare Diseases Drives Adoption of Oligonucleotide-Based Therapeutics in Precision Medicine
      • Growing Investment in Antisense Oligonucleotides and RNA Interference Therapies Propels Growth in the Oligonucleotide Therapeutics Market
      • Advancements in RNA-Based Therapeutics, Including siRNA and mRNA, Strengthen the Business Case for Expanding Oligonucleotide Drug Development Pipelines
      • Increasing Focus on Gene Silencing and Exon Skipping Techniques Using Oligonucleotides Spurs Market Growth in Neurological Disorders
      • Rise of CRISPR and Gene Editing Technologies Expands the Addressable Market Opportunity for Oligonucleotide Therapeutics
      • Improved Oligonucleotide Delivery Systems, Including Lipid Nanoparticles and Conjugation Technologies, Drive the Efficacy of Therapeutic Applications
      • FDA Approvals of Key Oligonucleotide-Based Drugs Accelerate Market Growth and Boost Investor Confidence in Therapeutic Development
      • Growing Application of Oligonucleotides in Oncology, Including Targeted Cancer Therapies, Generates Demand for Advanced Therapeutics
      • Increasing Collaborations Between Pharma and Biotech Companies and Oligonucleotide Specialists Boost Therapeutic Innovation
      • Technological Advancements in Nucleic Acid Synthesis and Modifications Propel the Development of Next-Generation Oligonucleotide Drugs
    • 4. GLOBAL MARKET PERSPECTIVE
      • TABLE 1: World Oligonucleotide Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
      • TABLE 2: World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 3: World Historic Review for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 4: World 16-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
      • TABLE 5: World Recent Past, Current & Future Analysis for Antisense / RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 6: World Historic Review for Antisense / RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 7: World 16-Year Perspective for Antisense / RNAI Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 8: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 9: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 10: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 11: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 12: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 13: World 16-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 14: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 15: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 16: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 19: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

    III. MARKET ANALYSIS

    • UNITED STATES
      • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
      • TABLE 20: USA Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 21: USA Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 22: USA 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 23: USA Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 24: USA Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 25: USA 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • CANADA
      • TABLE 26: Canada Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 27: Canada Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 28: Canada 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 29: Canada Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 30: Canada Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 31: Canada 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • JAPAN
      • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
      • TABLE 32: Japan Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 33: Japan Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 34: Japan 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 35: Japan Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 36: Japan Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 37: Japan 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • CHINA
      • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
      • TABLE 38: China Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 39: China Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 40: China 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 41: China Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 42: China Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 43: China 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • EUROPE
      • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
      • TABLE 44: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 45: Europe Historic Review for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 46: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
      • TABLE 47: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 48: Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 49: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 50: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 51: Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 52: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • FRANCE
      • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
      • TABLE 53: France Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 54: France Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 55: France 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 56: France Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 57: France Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 58: France 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • GERMANY
      • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
      • TABLE 59: Germany Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 60: Germany Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 61: Germany 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 62: Germany Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 63: Germany Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 64: Germany 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • ITALY
      • TABLE 65: Italy Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 66: Italy Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 67: Italy 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 68: Italy Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 69: Italy Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 70: Italy 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • UNITED KINGDOM
      • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
      • TABLE 71: UK Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 72: UK Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 73: UK 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 74: UK Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 75: UK Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 76: UK 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • REST OF EUROPE
      • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 78: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 79: Rest of Europe 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 81: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 82: Rest of Europe 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • ASIA-PACIFIC
      • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
      • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 84: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 85: Asia-Pacific 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 87: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 88: Asia-Pacific 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
    • REST OF WORLD
      • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 90: Rest of World Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 91: Rest of World 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
      • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 93: Rest of World Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 94: Rest of World 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030

    IV. COMPETITION

    • 샘플 요청 목록
    0 건의 상품을 선택 중
    목록 보기
    전체삭제